US 12,440,543 B2
Botulinum toxin type a complex, and formulation thereof and usage method therefor
Tzu-Wen Tsau, Taipei (TW); Yung-Kai Wang, Taipei (TW); Kuan-Cheng Shen, Taipei (TW); Yueh-Chin Wu, Taipei (TW); Cheng-Der Tony Yu, Taipei (TW); and Yu-Chun Tseng, Taipei (TW)
Assigned to OBIGEN PHARMA, INC., Zhubei (CN)
Appl. No. 17/623,072
Filed by OBIGEN PHARMA, INC., Zhubei (TW)
PCT Filed Mar. 31, 2020, PCT No. PCT/CN2020/082450
§ 371(c)(1), (2) Date Dec. 27, 2021,
PCT Pub. No. WO2021/195968, PCT Pub. Date Oct. 7, 2021.
Prior Publication US 2022/0257730 A1, Aug. 18, 2022
Int. Cl. A61K 38/48 (2006.01); A61K 8/66 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/42 (2017.01); A61K 47/64 (2017.01); C07K 14/33 (2006.01); C12N 9/52 (2006.01)
CPC A61K 38/4893 (2013.01) [A61K 8/66 (2013.01); A61K 9/0019 (2013.01); A61K 9/19 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/183 (2013.01); A61K 47/26 (2013.01); A61K 47/42 (2013.01); A61K 47/64 (2017.08); C07K 14/33 (2013.01); C12N 9/52 (2013.01); C12Y 304/24069 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising a Clostridium botulinum toxin Type A complex and a formulation buffer comprising human serum albumin, sodium chloride and polysorbate 80 dissolved in citrate buffer, wherein the Clostridium botulinum toxin Type A complex comprises:
a HA70 component comprising the amino acid sequence of SEQ ID NO. 1;
a HA17 component comprising the amino acid sequence of SEQ ID NO. 2;
a HA33 component comprising the amino acid sequence of SEQ ID NO. 3;
a NTNH component comprising the amino acid sequence of SEQ ID NO. 4;
a BoNT/A1 component comprising the amino acid sequence of SEQ ID NO. 5; and
wherein the Clostridium botulinum toxin Type A complex has a molecular weight of 740-790 kDa.